TECH CRUNCH article on Artificial Intelligence highlighting IPMD
and Cancer Detection Technology
August 12, 2016 : The healing power of Artificial Intelligence
An article is published on the Techcrunch Networks featuring how IPMD's technology can detect cancer with very high accuracy based on highly advanced molecular diagnostics techniques to identify all responsible or related biomarkers against the target diseases based on the relatively non-invasive human samples such as blood, urine, saliva and the Artificial Intelligence.
IPMD Scientific Adviser to be Keynote Speaker at 2016 Seoul
Mr. Min Lee, IPMD, Inc. Founder, CEO & President and Dr. Sean Young, a Scientific Adviser at IPMD, Inc., are officially invited to Seoul Forum 2016, where Mr. Min Lee is invited as a phenomenal business leader, and Dr. Sean Young is invited as a Keynote Speaker. The Forum is a global event held annually in Seoul Korea , provides an opportunity for all in attendance to observe and partake in a discussion of the future direction of international business and economics. Attended regularly by globally renowned scholars, global business leaders, politicians, and economic experts, it is viewed by many as a meeting of the minds from around the world. The theme of this year’s forum is how artificial intelligence (AI) and AI application in the medical field will shape the future of the global economy. Dr. Young, also the founder of the University of California Institute for Prediction Technology, will speak about IPMD’s diagnostic testing device, called “Lablet.” Discussed will be the future of artificial intelligence disease diagnostics and its application at the individual level, as well as when scaled for large populations. Dr. Young will address the different perspectives held around whether technological innovation will eventually lead to popular wearable devices, while also predicting that many “personalized technologies will help people everywhere test for diseases, improve their productivity, and make better decisions.”
IPMD Files Patent for Artificial Intelligence Chronic Diseases
May 6, 2016
An award-winning law firm and representing IPMD, Inc., Nixon Peabody filed a patent application covering a system for diagnosing chronic diseases that uses cutting edge artificial intelligence algorithms. Called “Lablet Artificial Intelligence Platform" developed by IPMD, uses an algorithm similar to Google’s AlphaGo and IBM’s Watson to train their artificial intelligence. However, with one key difference. While Watson relies on medical images acquired from methods such as CT and MRI scans as input data, IPMD uses a data-driven multivariate statistical approach. Employing a highly sophisticated biochip to analyze a small amount of human sample (fingertip blood, saliva, urine, etc.), Lablet eliminates the need for patients traveling long routes from remote locations to health centers where expensive equipment is used to gather input for diagnostic testing. Within the human sample, Lablet will simultaneously analyze thousands of biomarkers using short single strands of DNA or RNA oligonucleotides, which act similarly to antibodies. This is conducted by folding and adopting three-dimensional structures based on the interactions of complementary base pairs. This three-dimensional configuration is key to allowing oligonucleotides to have the ability to bind to specific biomarkers. By using this process, Lablet captures significant biomarkers found in the sample, thus allowing for artificial intelligence to then correlate identified patterns to either a diseased or not diseased state. The more input data inserted into the Lablet device, the greater the accuracy of the diagnostic results. The company’s current goal is to achieve at least 99% accuracy.
IPMD Files Patent for Point-of-Care Device for Detecting
April 13, 2016
Providing basic medical care to those in impoverished or remote regions throughout the world has been a major obstacle in the field of medicine for decades. Basic care not only means the minimum treatment necessary but essential diagnostic testing as well. Without diagnostic testing infectious diseases advance with increasing risks of strain mutations and drug resistances, further exacerbating areas already strongly affected by widespread diseases. This makes this week’s events particularly significant. Taking a major step forward in its objective to provide access to basic care for those who are missing central medical attention, IPMD, Inc. filed its patent application for a point-of-care medical device to detect infectious diseases with Nixon Peabody, a nationally ranked law firm based in Palo Alto, California. With IPMD’s point-of-care device, medical care, once seen as stationary and limited, is now portable and obtainable. Integrating loop mediated isothermal amplification (LAMP) technology, providing 97.7% sensitivity and 99% specificity, IPMD’s device can be operationalized in rural clinics lacking major hospital grade laboratory equipment. Yet, by designing the device to be compatible with inexpensive disposable cartridges, IPMD reduces overall manufacturing costs, making it within financial feasibility. Other features of the device include, faster result feedback with laboratory grade accuracy, thereby increasing the patient’s chances for recovery. Requiring little operational training and running on rechargeable batteries has also made the need for highly trained professionals and access to electricity a non barrier.
IPMD Sign R&D Partnership with U.S. Department of Veterans
Affairs & Brentwood Biomedical Research Institute
Feb 25, 2016
IPMD, and the U.S. Department of Veterans Affairs, a Federal Government Agency, as represented by VA Greater Los Angeles Healthcare System and Brentwood Biomedical Research Institute, have signed agreement to jointly develop Multiplex Loop Mediated Isothermal Amplification (m-LAMP) Technology for Point of Care (POC) Diagnosis of Diseases. IPMD and VA are aiming to develop point of care medical device that can screen and diagnose diseases using very small amount of human samples to achieve the goal of non-invasive diseases screening and diagnostics device development that will give quality test results of centralized laboratory. The current specific aims are for Optimization and Verification of the Point of Care Medical Device Developed by IPMD, Inc. Specific Aim 1 : Optimization of LAMP technology to detect diseases (viral, cancer, and bacterial), Specific Aim 2 : Optimization of LAMP reaction detection methods, and Specific Aim 3 : Optimization of microfluidic based cartridge system. Once the co-development are completed, we expect to reduce medical cost in huge scale in general due to simplify the entire current gold standard screen and diagnosis procedures while achieving as high test results as the gold standard procedures.
IPMD Creates Internship Program for UC Berkeley Students
September 1, 2015
Inspiring the next generation of scientists in the Bay Area, IPMD’s internship program provides U.C. Berkeley students with hands-on experience alongside notable scientists in the field. Throughout the program, interns work with experienced professionals to develop a medical device. More specifically, students are exposed to multiple stages of research and development and assist in the design and creation of a mobile, diagnostic instrument with patented technology. An all-in-one point-of-care medical device, IPMD’s latest cutting-edge invention will test patients for various infectious diseases on-site using one platform, followed by immediate results. In addition, interns also work on projects involving wearable health management platforms for targeted medical objectives. Such objectives include, but are not limited to, monitoring body levels for diabetes control, risk of malnutrition, harmful toxins, and unsafe hormonal imbalances.
Finally, some interns work on projects involving adipose stem cell and urine derived stem cell to treat Alzheimer Diseases, Liver Diseases, and Glaucoma. Other students interns are working on developing artificial intelligence platform that can interact with humans to optimize the psychological health. Through these different projects students learn to apply what they have learned inside the classroom to real applications that are useful to the human kinds. By providing these bright young minds the resources to experiment and the expertise to learn from, IPMD’s internship program is training U.C. Berkeley students to become the next leaders in science and medicine; starting with opening their eyes to the power of their knowledge.